Video webcast now available  here

Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses

Akari Therapeutics reports positive preclinical data for AKTX-101 in urothelial cancer, showing effi

Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug co

AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial canc

Expanded the Company's strategic position in novel ADC payloads through a research collaboration

AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1

Discussion explores how combining complementary payload technologies may unlock new therapeutic oppo

Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed below its 200-day movin

Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, acceleratin

Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark

Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug co

TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an

Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues

Globally recognized leader in early-phase oncology clinical development and experimental therapeutic

Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined wit

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&

Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven

kari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug con

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagas

US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $39

Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's mas

Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's

Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD

US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe

Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinica

Akari Therapeutics shares are surging after preclinical data showed AKTX‑101 synergized with KRAS in

US stocks rise with the Dow gaining 250 points. Health care shares jump while energy stocks fall. BJ

Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Othe

An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates

An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates

Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug co

TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an

Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wedne

Akari Therapeutics PLC (NASDAQ:AKTX) sees stock growth fueled by Q1 2026 earnings optimism and a new

Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug co

Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molec